Logo

BeiGene Signs an Exclusive Option and License Agreement with Leap Therapeutics for DKN-01

Share this

BeiGene Signs an Exclusive Option and License Agreement with Leap Therapeutics for DKN-01

Shots:

  • Leap to receive $3M up front- up to $132M development- regulatory- and sales milestones plus royalties on sales of product. BeiGene to get an exclusive option to license DKN-01- for its development and commercialization in Asia (ex-Japan)- Australia- New Zealand
  • Post the results of proof-of-concept study BeiGene will exercise the option and will pay additional payments to Leap. Additionally- BeiGene to make $5M equity investment in Leap as part of the contemporaneous $27M equity financing 
  • DKN-01 is a mAb that blocks & binds the activity of Dickkopf-1 (DKK1) protein and will be evaluated in combination with tislelizumab and CT among 40 patients & 20 patients with 2L gastric cancer (GC) /gastroesophageal junction cancer (GEJ) & 1L GC/GEJ respectively- with expected initiation in H1’20

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions